Anika Therapeutics | ANIK - Pre Utilidad Fiscal

Precio De Mercado
15.19
Cambio Diario
0.24 1.61%
Mensual
1.81%
Anual
4.83%
Q2 Expectativa
14.54




Pre Utilidad Fiscal Cambio Fecha
Abbott USD 2.39B 27M 2026-03
Agenus USD -10.61M 263.52M 2025-12
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -326.93M 41.77M 2025-12
Integra LifeSciences USD 4.31M 11.13M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
J&J USD 7.82B 2.86B 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
MacroGenics USD -14.93M 31.75M 2025-12
Merit Medical Systems USD 51.06M 22.12M 2025-12
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Smith & Nephew USD 469M 70M 2025-12
Stryker USD 1.7B 676M 2025-12
Surmodics USD -5.9M 1.61M 2025-06
Veracyte USD 29.97M 10.66M 2026-03
Xencor USD -4.27M 1.76M 2025-12
Zimmer Biomet Holdings USD 98M 320.7M 2025-12